Generate Biomedicines (GENB) News
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
9.54-0.83 (-8.00%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GENB news summary
We found 9 recent headlines mentioning Generate Biomedicines (GENB): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. GENB is making an outsized move today, down 8.00% at $9.54, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Generate Biomedicines, Inc. reports Q3 results", was published by Seeking Alpha on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Generate Biomedicines headlines
- Generate Biomedicines, Inc. reports Q3 resultsSeeking Alpha
- Generate Biomedicines Reports Q3 Results; Cash Runway Extends Into First Half Of 2028; Stock Down(RTTNews) - Generate Biomedicines, Inc. (GENB), a clinical-stage generative biology company, reported financial results for the third quarter ended September 30, 2026, highlighting continued clinical…NasdaqGENB, LEN.B
- Generate Biomedicines, Inc Q3 Sales Decline(RTTNews) - Generate Biomedicines, Inc (GENB) announced Loss for third quarter of -$87.657 millionNasdaqGENB, BF.A
- Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business UpdateGB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a yearGlobeNewswire
- Nvidia Plays Kingmaker Again. Why the Meta Deal Is a Winning Move.Key PointsYou can add Meta to the long list of AI stocks Nvidia has invested in.NasdaqNVDA, META, NOK, INTC
- Generate Biomedicines to Participate in November Investor ConferencesSOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at…GlobeNewswire
- Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic Diseases(RTTNews) - Artificial intelligence is playing an increasingly important role in drug development, and Zealand Pharma (ZEAL) and Generate Biomedicines are the latest companies to combine their…NasdaqET, GENB
- Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGlobeNewswire
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesPress release – No. 20 / 2026GlobeNewswire